How ERAS-0015 Trial Progress and Asia Licensing Expansion Will Impact Erasca (ERAS) Investors

Erasca recently reported encouraging clinical progress for its lead pan-RAS candidate ERAS-0015, including partial responses in patients and no dose-limiting toxicities, while also expanding its licensing agreement with Joyo Pharmatech to cover China, Hong Kong, and Macau. The expanded Joyo Pharmatech agreement gives Erasca global control over development and future data releases, potentially tightening coordination between clinical results and future commercial planning. Next, we’ll examine…Read More